123 related articles for article (PubMed ID: 37879973)
1. Corrigendum to "Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c/SCD1 signaling pathway and modulating gut microbiota" [Int. Immunopharmacol. 99 (2021) 108065].
Liu HJ; Cao ST; Wen BY; Han X; Li Y; Li S; Li J; Zhang L
Int Immunopharmacol; 2023 Dec; 125(Pt A):111084. PubMed ID: 37879973
[No Abstract] [Full Text] [Related]
2. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway" [Int. Immunopharmacol. 75 (2019) 105759].
Wen S; Wei Y; Zhang X; Bai F; Tan S; Nie J; Wei J; Lin X
Int Immunopharmacol; 2021 Mar; 92():107344. PubMed ID: 33418247
[No Abstract] [Full Text] [Related]
4. Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE
Ma Y; Chen K; Lv L; Wu S; Guo Z
Biomed Pharmacother; 2019 May; 113():108753. PubMed ID: 30856537
[TBL] [Abstract][Full Text] [Related]
5. Phloridzin Ameliorates Lipid Deposition in High-Fat-Diet-Fed Mice with Nonalcoholic Fatty Liver Disease
Liu H; Chen Y; Wen Y; Zhu S; Huang S; He L; Hou S; Lai X; Chen S; Dai Z; Liang J
J Agric Food Chem; 2021 Aug; 69(31):8671-8683. PubMed ID: 34342231
[TBL] [Abstract][Full Text] [Related]
6. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
Ren T; Zhu J; Zhu L; Cheng M
Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-related receptor γ controls sterol regulatory element-binding protein-1c expression and alcoholic fatty liver.
Kim DK; Kim YH; Lee JH; Jung YS; Kim J; Feng R; Jeon TI; Lee IK; Cho SJ; Im SS; Dooley S; Osborne TF; Lee CH; Choi HS
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Dec; 1864(12):158521. PubMed ID: 31479733
[TBL] [Abstract][Full Text] [Related]
8. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
10. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism.
Lei Y; Tang L; Chen Q; Wu L; He W; Tu D; Wang S; Chen Y; Liu S; Xie Z; Wei H; Yang S; Tang B
Nat Commun; 2022 Nov; 13(1):6862. PubMed ID: 36369291
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum to "Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 128 (2024) https://doi.org/10.1016/j.intimp.2023.111466].
Geng H; Zhang H; Cheng L; Dong S
Int Immunopharmacol; 2024 Apr; 131():111873. PubMed ID: 38514302
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int. Immunopharmacol. 77 (2019) 105968].
Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
Int Immunopharmacol; 2020 Jul; 84():106318. PubMed ID: 32115350
[No Abstract] [Full Text] [Related]
13. Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice.
Xu J; He X; Huang X; Zhang F; Ren X; Asakiya C; Li Y; Huang K
Front Pharmacol; 2022; 13():851342. PubMed ID: 35586049
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Gypsophila elegans isoorientin-2″-O-α-L-arabinopyranosyl ameliorates porcine serum-induced immune liver fibrosis by inhibiting NF-κB signaling pathway and suppressing HSC activation" [Int. Immunopharmacol. 54 (2018) 60-67].
Bai F; Huang Q; Wei J; Lv S; Chen Y; Liang C; Wei L; Lu Z; Lin X
Int Immunopharmacol; 2023 Sep; 122():110697. PubMed ID: 37500383
[No Abstract] [Full Text] [Related]
15. Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis.
Zhou LM; Fan JH; Xu MM; Xiong MY; Wang QJ; Chai X; Li XD; Li XG; Ye XL
Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166639. PubMed ID: 36638873
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
18. Mussel polysaccharide α-D-glucan (MP-A) protects against non-alcoholic fatty liver disease via maintaining the homeostasis of gut microbiota and regulating related gut-liver axis signaling pathways.
Wu J; Shao H; Zhang J; Ying Y; Cheng Y; Zhao D; Dou X; Lv H; Li S; Liu F; Ling P
Int J Biol Macromol; 2019 Jun; 130():68-78. PubMed ID: 30797009
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum to "Nobiletin ameliorates myocardial ischemia and reperfusion injury by attenuating endoplasmic reticulum stress-associated apoptosis through regulation of the PI3K/AKT signal pathway" [Int. Immunopharmacol 73 (2019) 98-107].
Zhang BF; Jiang H; Chen J; Guo X; Li Y; Hu Q; Yang S
Int Immunopharmacol; 2023 Sep; 122():110769. PubMed ID: 37573240
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Amisulpride attenuates 5-fluorouracil-induced cognitive deficits via modulating hippocampal Wnt/GSK-3β/β-catenin signaling in Wistar rats" [Int. Immunopharmacol. 124(Part A) (2023) 110945].
Raafat RS; Habib MZ; AbdElfattah AA; Olama NK; Abdelraouf SM; Hendawy N; Kamal KA; Nawishy SA; Aboul-Fotouh S
Int Immunopharmacol; 2023 Dec; 125(Pt B):111203. PubMed ID: 37978013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
